Prophylactic Administration of Surfactant in Extremely Premature Infants
Table 2
Mortality and morbidity.
Prophylactic surfactant group (observational period)
selective surfactant group (historical control)
Significance
Death until term
5 (16%)
6 (18%)
n.s.
IVH II
4 (13%)
3 (9%)
n.s.
PVL
3 (10%)
1 (3%)
n.s.
Pneumothorax
1 (3%)
4 (9%)
n.s.
CLD
8 (26%)
13 (38%)
n.s.
PIE
0 (0%)
3 (9%)
n.s.
Need for mechanical ventilation (h per patient)
Diagnosis of PDA
22 (71%)
28 (82%)
n.s.
Treatment of PDA
21 (68%)
26 (68%)
n.s.
NEC
1 (3%)
5 (15%)
n.s.
Nosocomial infection
14 (45%)
15 (44%)
n.s.
Postnatal steroids
19 (61%)
21 (62%)
n.s.
Surfactant doses
41
62
n.s.
Surfactant doses per patient
1.3
1.8
n.s.
IVH:intraventricular hemorrhage; PVL:periventricular leukomalacia; CLD:chronic lung disease (need of additional oxygen after 36 weeks gestational age); PIE:pulmonary interstitial emphysema; PDA:patient ductus arteriosus; NEC:necrotizing enterocolitis (stadium II or III according to Bell).
